Multiple Sclerosis

>

The NeurologyLive® MS Disease Spotlight page offers specific updates and coverage on the latest expert conversations and data readouts related to the treatment and management of patients with multiple sclerosis and demyelinating disorders.

Latest News

Collateral Damage to Patients From Formulary Restrictions in Multiple Sclerosis (MS): Perspectives from an MS Specialist, a Patient, and a Neurologist in Training
Collateral Damage to Patients From Formulary Restrictions in Multiple Sclerosis (MS): Perspectives from an MS Specialist, a Patient, and a Neurologist in Training

July 22nd 2025

Navigating insurance hurdles for multiple sclerosis treatments poses significant risks, as seen in a patient's devastating relapse after denied care.

30-Year Analysis Suggests Regression of Progressive Multiple Sclerosis, In Part to Advances in Therapeutics
30-Year Analysis Suggests Regression of Progressive Multiple Sclerosis, In Part to Advances in Therapeutics

July 12th 2025

Aetna Joins UnitedHealthcare and Anthem in Authorizing PoNS Device Claims for Patients With MS
Aetna Joins UnitedHealthcare and Anthem in Authorizing PoNS Device Claims for Patients With MS

June 18th 2025

NeuroVoices: Tiffany Malone, MSW, MSCS, on Combating Loneliness in MS Care Through Connection and Community Programs
NeuroVoices: Tiffany Malone, MSW, MSCS, on Combating Loneliness in MS Care Through Connection and Community Programs

June 18th 2025

Sam Hooshmand, DO (Credit: Medical College of Wisconsin)
Clinical Insight on Challenges and Evolving Strategies in Advanced Multiple Sclerosis Care

June 7th 2025

More News

Siponimod Significantly Slows MS Disability Progression in Patients With Shorter Disease Duration

Siponimod Significantly Slows MS Disability Progression in Patients With Shorter Disease Duration

Marco Meglio
February 27th 2020
Article

Patients with a disease duration of <16 years demonstrated a significantly greater reduction in risk for confirmed disability progression (CDP) at 3 and 6 months.

Siponimod Delays Time to Wheelchair Use in Secondary Progressive MS

Siponimod Delays Time to Wheelchair Use in Secondary Progressive MS

Matt Hoffman
September 13th 2019
Article

After showing significant benefits in delayed disease progression in patients with secondary progressive MS, new data suggests siponimod can delay the time to wheelchair dependence by 4 years.

Siponimod Cleared for Treatment of Secondary Progressive MS

Siponimod Cleared for Treatment of Secondary Progressive MS

Matt Hoffman
March 27th 2019
Article

Marketed as Mayzent, the selective sphingosine 1-phosphate receptor modulator is the first treatment for patients with active secondary progressive multiple sclerosis in almost 15 years.

Siponimod NDA Accepted by FDA for Secondary Progressive MS

Siponimod NDA Accepted by FDA for Secondary Progressive MS

Jenna Payesko
October 9th 2018
Article

If approved, siponimod would be the first oral disease-modifying therapy with the potential to delay secondary progressive multiple sclerosis progression.

<1
...
101112131415>
© 2025 MJH Life Sciences

All rights reserved.